Korea Chorus Accelerates Final Preparations for Commercial Production of 'Sputnik V' Vaccine

On the 20th, the second dose validation badge batch of the 'Sputnik V' vaccine by Korea Corus is being loaded onto a Korean Air flight for shipment to Russia. (Provided by Korea Corus)

[Asia Economy Reporter Lee Chun-hee] Korea Corus, which is in charge of the domestic contract development and manufacturing organization (CDMO) for Russia's 'Sputnik V' vaccine, is hastening preparations for commercial production.

Korea Corus announced on the 21st that it shipped the second dose 'Validation Batch' of the Sputnik V vaccine on the 20th and sent it to Russia via air freight. Earlier, Korea Corus had shipped the Validation Batch for the first dose on the 1st of this month.

Validation is a procedure that guarantees and verifies whether a specific process continuously produces products that meet established specifications and quality factors. It is the final stage of pharmaceutical contract manufacturing, and passing this stage brings the shipment of commercial production quantities within reach.

A Korea Corus official explained, "We produced the Validation Batch together during the visit of researchers from the Russian sovereign wealth fund (RDIF)," adding, "Through this, we have established a foundation for complete technology transfer and smooth commercial production." Korea Corus plans to promptly ship commercial quantities once the local regulatory approval process in Russia is completed.

Currently, Korea Corus has been discussing domestic contract production of the Sputnik V vaccine with RDIF since last year. Through this, they have finalized agreements for 150 million doses produced by Gilead and Korea Corus itself, and 500 million doses produced through a consortium of domestic bio companies.

This content was produced with the assistance of AI translation services.